Chemomab Therapeutics price to book ratio CMMB

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 10.7×; Apr 2025
7-year median: 3.0×
7-year range: 0.2× to 45.7×
Peer median: 2.3×

Chemomab Therapeutics' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Apr 2025, at 10.7×.

On the days it had one over the last 7 years, its median was 3.0×, from 0.2× in Dec 2023 to 45.7× in Mar 2021.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	10.7×	10.7×	21.7×
2024	20.4×	0.2×	20.5×
2023	0.2×	0.2×	9.9×
2022	0.8×	0.4×	17.9×
2021	1.2×	1.2×	45.7×
2020	12.0×	1.6×	16.5×

Against its peers

Companies in Drug Manufacturers - General nearest Chemomab Therapeutics' size, closest first, today.

Company	Price to book ratio
CMMBChemomab Therapeutics	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
IRWDIronwood Pharmaceuticals	n/m
PBYIPuma Biotechnology	4.1×
ARVNArvinas	0.8×
COLLCollegium Pharmaceutical	2.4×
ABUSArbutus Biopharma	3.2×
AMPHAmphastar Pharmaceuticals	1.4×
OMEROmeros	n/m
PCRXPacira BioSciences	2.2×
Peer median	2.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Chemomab Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.